Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Hits 52-Week High

NEW YORK (GenomeWeb News) – After matching a 52-week high of $23 on Monday before pulling back to close at $22.33 on the Nasdaq, up 6.4 percent for the day, shares of Sequenom hit a new 52-week high on Tuesday morning of $24.50.
 
The San Diego-based firm’s stock bucked the trend on a dismal Monday for the stock market, which saw the Dow Jones Industrial Average lose 241.81, or 2.1 percent, while the Nasdaq dropped 2 percent. The $23 per share price matched the firm’s 52-week high reached on July 16.
 
Sequenom’s shares have risen sharply since the firm announced in early June positive results from a clinical study of its Down syndrome test, with no false positives reported in the study. It expects to release the results of a second, larger study of the test later this year.
 
Some analysts have speculated that the market for such a test is potentially worth more than $2 billion.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.